Abstract
Observational studies over 20years have suggested that a patent foramen ovale (PFO) is an important cause of cryptogenic stroke in young individuals; case series and registries suggest that PFO closure confers superior protection from recurrent transient ischemic attack (TIA) and stroke. Recently completed randomized clinical trials did not confirm this hypothesis, but have provided reassurance that the risk of recurrent stroke is low at 1.5%/yr. A target subset that may benefit are those with ischemic stroke, a large right-to-left shunt, and an atrial septal aneurysm. Further study is needed to determine the optimum strategy to reduce the long-term stroke risk in a lifetime of varying situational risk factors and temporary interruptions of medical therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Treatment Options in Cardiovascular Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
